Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
US Army
Citi
Express Scripts
Julphar
Merck
Fish and Richardson
Boehringer Ingelheim
Chinese Patent Office

Generated: January 18, 2018

DrugPatentWatch Database Preview

Noden Pharma Company Profile

« Back to Dashboard

Summary for Noden Pharma
International Patents:208
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Noden Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-003 Jan 18, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-004 Jan 18, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-002 Mar 5, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-002 Mar 5, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-001 Mar 5, 2007 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-004 Jan 18, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-002 Jan 18, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-002 Jan 18, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-003 Jan 18, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-003 Jan 18, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NODEN PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 150 mg/12.5 mg, 150 mg/25 mg, 300 mg/12.5 mg, 300 mg/25 mg ➤ Subscribe 3/7/2014
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 12/13/2013

Non-Orange Book US Patents for Noden Pharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,659,065 Alpha-aminoalkanoic acids and reduction products ➤ Subscribe
9,023,894 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases ➤ Subscribe
5,606,078 3,5-Disubstituted tetrahydrofuran-2-ones ➤ Subscribe
8,007,824 Galenic formulations of organic compounds ➤ Subscribe
5,627,182 .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides ➤ Subscribe
5,705,658 Azido containing tetrahydro furan compounds ➤ Subscribe
5,654,445 .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acids ➤ Subscribe
5,646,143 .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides ➤ Subscribe
8,618,174 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases ➤ Subscribe
7,683,054 Galenic formulations of organic compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Noden Pharma Drugs

Supplementary Protection Certificates for Noden Pharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1507558/01 Switzerland ➤ Subscribe PRODUCT NAME: ALISKIREN + AMLODIPIN + HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: SWISSMEDIC 61678 05.07.2011
0678503/04 Switzerland ➤ Subscribe PRODUCT NAME: ALISKIREN + AMLODIPIN; REGISTRATION NO/DATE: SWISSMEDIC 61454 05.07.2011
00499 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
2011 00027 Denmark ➤ Subscribe
13/058 Ireland ➤ Subscribe 2013/058 DECLARED INVALID WITH ARTICLE 15 1C OF REGULATION EC NO. 469/2009
564 Luxembourg ➤ Subscribe 91564, EXPIRES: 20200407
2007 00049 Denmark ➤ Subscribe
00385 Netherlands ➤ Subscribe PRODUCT NAME: ALISKIREN, DESGEWENST IN DE VORM; REGISTRATION NO/DATE: 58935 01-04 20081028
0678503/01 Switzerland ➤ Subscribe PRODUCT NAME: ALISKIREN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58050 29.06.2007
2009 00009 Denmark ➤ Subscribe
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
UBS
Baxter
Boehringer Ingelheim
QuintilesIMS
Covington
Accenture
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot